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Abstract 
The use of recombinant BoNT domains has been proposed as a means to develop strategies to treat 
and prevent botulism. Here, details on the molecular cloning, protein expression, purification, and 
immunoreactivity of BoNT/F domains from Clostridium botulinum are presented. Initially, full-
length synthetic genes encoding recombinant BoNT/F domains (catalytic, translocation, and 
receptor binding) were designed and cloned into Escherichia coli for expression. Recombinant 
proteins were then purified through GST affinity chromatography preceding elution of GST-free 
recombinant domains by thrombin protease. Soluble recombinant proteins encoding catalytic light 
chain and translocation N-terminal heavy chain were subsequently used to perform in vivo 
immunization. Polyclonal mouse antibodies specific to these domains were raised, confirmed by 
Western blot analysis and elevated immunoreactivity was identified through indirect ELISA. In 
conclusion, availability of the recombinant protein provides an effective system to study the 
immunological aspects of BoNT/F and corresponding applications in pathogen detection and 
vaccine candidacy.  
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Introduction 
Botulinum neurotoxins (BoNTs), the most 
potent of all biological substances known to 
date, are produced by several species of the 
genera Clostridia (C. botulinum, C. butyricum, 
and C. baratii) [1-3]. Seven immunologically 
distinct botulinum neurotoxin serotypes 
BoNTs/A-G are produced and implicated in 
botulism poisoning [4]. Botulism is a serious 
neuroparalytic disease [5], which generally 
occurs through ingestion of preformed toxin 
or rarely, through infection of wounds. The 
Center for Disease Control and Prevention 
(CDC) classifies BoNTs, among the six 
highest risk threat agents for bioterrorism 
“class A biological warfare agent” [6, 7]. 
Despite their potential to be used for 
deleterious purposes, BoNTs have increasing 
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applications in cosmetics [8] and therapeutics 
for the treatment of numerous dystonias, 
inflammation, and chronic pain [9-11]. 
Botulinum neurotoxin serotype F (BoNT/F), is 
a member of the botulinum neurotoxin family 
as a single ~150 kDa inactive polypeptide 
chain post-translationally nicked, forming a 
dichain consisting of a C-terminal ~100 kDa 
heavy chain (HC) and a N-terminal ~50 kDa 
light chain (LC) linked by a disulphide bond 
[12, 13]. BoNT/F cleaves its substrate vesicle 
associated membrane protein (VAMP) at 
position (Gln58-Lys59) [14, 15], one of three 
neuronal proteins associated with exocytosis; 
subsequently inhibiting acetylcholine release, 
resulting in death by flaccid paralysis [16, 17]. 
Each BoNT/F partial fragment; light chain 
catalytic domain (rF-LC), N-terminal half of 
the heavy chain translocation domain (rF-
HN), the C-terminal half of the heavy chain 
receptor binding domain (rF-HC), and C-
terminal quarter part of the heavy chain 
receptor binding domain (rF-HCc) plays a 
specific role in the toxicity mechanism [18, 
19]. Botulinum neurotoxin LCs operate by 
zinc dependent proteolysis involved in 
neurotransmitter exocytosis from presynaptic 
termini [20]. Botulinum neurotoxin HNs 
possesses channel-forming capability in the 
acidic environment of the endosome, allowing 
internalization of the toxin, while HCs are 
involved in specific binding to the presynaptic 
membrane via gangliosides and a protein co-
receptor [21]. Lastly, the HCc region of 
BoNTs are known to harbor the receptor 
binding neutralizing epitopes which are targets 
for antibodies that can specifically bind to the 
receptor, and show neutralizing activity 
against BoNT toxicity [22]. 
Thus, it is imperative to construct each 
domain for the analysis of their molecular and 
biochemical activities as well as for the 
development of potential neutralizing 
antibodies specific to each. To achieve this 
goal, BoNT/F domains from C. botulinum 
were cloned and expressed using a high 
expression vector and compatible host E. coli 
strains to obtain high quality of recombinant 
proteins suitable for administration into mice. 
 
Methods 
Chemicals, Buffers, and Reagents 
Components related to DNA manipulation, 
including Ex-Taq polymerase, dNTP, and 
restriction enzymes were purchased from 
Takara Bio. Inc., (Shiga, Japan). Luria Bertani 
(LB) media and cell culture media were 
purchased from Becton Dickinson and 
Company (MD, USA) and Hyclone (UT, 
USA) respectively. Additional chemicals 
including ampicillin, IPTG, Freund’s 
complete and incomplete adjuvant, and 
buffers were purchased from Sigma Aldrich 
(MO, USA).  
 
Bacterial strains, plasmids, and purification 
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systems 
C. botulinum type F strain Langeland [23] and 
BoNT/F (Wako Pure Chemicals Ind., Osaka, 
Japan) was kindly supplied by Medy-Tox Inc. 
Plasmids pGEX-4T-1 (Amersham Pharmacia 
Biotech acquired by GE Healthcare, Uppsala, 
Sweden) and pET-32a(+) (Novagen, EMD 
Chemicals Inc., affiliate of Merck KGaA, 
Darmstadt, Germany) were used for the 
construction of expression vectors. E. coli 
strains DH5α (Takara Bio Inc.), BL21-
CodonPlus-RIL and BL21-CodonPlus(DE3)-
RIL (Stratagene, CA, USA) were used as host 
strains for propagation and expression of 
recombinant proteins, respectively. 
Glutathione-S-Transferase (GST) purification 
modules and thrombin protease were 
purchased from Amersham Pharmacia 
Biotech.  
 
Construction of BoNT/F domains  
Chromosomal DNA was isolated from C. 
botulinum F str. Langeland, which was used as 
the template for polymerase chain reaction 
(PCR) for all domains (Fig. 1). Forward and 
reverse primers for each domain were 
designed (Table 1) based on the published 
NCBI sequence of the Langeland genome 
(NC_009699). 
 
 
 
 
Synthetic genes encoding BoNT/F LC (light chain), catalytic 
domain (1308 bp); HN (N-terminal 1/2 of heavy chain), 
translocation domain (1266 bp); HC (C-terminal 1/2 of heavy 
chain), receptor binding domain (1263 bp); and HCc (far C-
terminal quarter part of heavy chain), (501 bp) were designed 
based on the published BoNT/F sequence (ORF: 883635-887471) 
Langeland str. (NCBI GenBank Accession: NC_009699) for the 
plasmid construction of each domain. 
bp indicates base pair of DNA. 
1kb marker is provided for scale. 
 
TABLE 1. Primers used for amplification of BoNT/F domains. 
aPrimer direction: F, forward; R, reverse. 
bDirection of each sequence is in 5' to 3' orientation (underlined) 
including restriction endonuclease sequence (bold) and inserted 
stop codon sequences (blue) for LC and HN reverse primers. 
cNucleotide positions based on published C. botulinum F str. 
Langeland genome sequence (NCBI Genbank accession: 
NC_009699). 
dRestriction endonucleases utilized to digest PCR amplified 
domain and vector for plasmid construction. 
 
Isolation of genomic DNA was done utilizing 
protocols and chemicals mentioned by Wizard 
Genomic DNA Purification Kit (Promega, WI, 
USA). PCR was performed using a Bio-Rad 
iCycler (CA, USA). Reaction mixtures were 
preheated for 5 min at 94 °C for initial 
denaturation and then 30 cycles of PCR 
(denaturation, annealing, and elongation) were 
performed for amplification of domains as 
follows: 1 min at 94 °C, 1 min at 57 °C, and 1 
min 30 sec at 72 °C for F-LC; 1 min at 94 °C, 
1 min at 50 °C, and 1 min 30 sec at 72 °C for 
F-HN and F-HC; 1 min at 94 °C, 1 min at 54.5 
°C, and 40 sec at 72 °C for F-HCc. Following 
completion of cycles, a final extension was 
LC 
1 kb 
Scale 
S      S  
HN HC 
1308 bp 1266 bp 
1263 bp 
HCc 
       501 bp   
 Native BoNT/F (3837 bp) 
883635                                                                                                              887471     
_____________________________________________________________________________________________________________________________ 
Primera  Sequence 5' ! 3'b      Nucleotide positionsc Restriction enzymesd  
_____________________________________________________________________________________________________________________________ 
F-LC-F  CGTGTCGACATGCCAGTTGTAATAAATAGTTTT   883635-883658  SalI        
F-LC-R  CCGGCGGCCGCTTATTTTCTAGGAATAACGCTCTT  884942-884922  NotI    
 
F-HN-F  CGTGGATCCGGTACAAAGGCGCCACCGCGACTA  884943-884966  BamHI    
F-HN-R  CCGCTCGAGTTAATATAAAATTAGAATTTTATC  886209-886188  XhoI     
 
F-HC-F   CGTGGATCCTTTAATAAATTATATAAAAAAATT  886209-886232  BamHI    
F-HC-R  CCGCTCGAGTTAGTTTTCTTGCCATCCATGCTC  887471-887448  XhoI    
 
F-HCc-F CGTGGATCCGATAAGTCTATTACTCAGAATTCA  886971-886994  BamHI    
F-HCc-R CCGCTCGAGTTAGTTTTCTTGCCATCCATGCTC  887471-887448  XhoI     
_____________________________________________________________________________________________________________________________ 
Fig.1: Schematic diagram demonstrating BoNT/F domains for cloning. 
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carried out for an additional 7 min at 72 °C. 
Amplified PCR products were purified by 
agarose gel elution kit (Intron Biotechnology, 
The Republic of Korea), and resultant PCR 
products were digested with restriction 
enzymes (Table 1) and subcloned into pGEX-
4T-1 vector using T4 ligase kit (Promega) for 
overnight at 16 °C, so that the correct reading 
frame was incorporated along the thrombin 
cleavage site under the GST gene 
(representative constructs made from 
MacVector 10.0.2 (NC, USA) software 
containing F-LC and F-HN domains are 
shown in Fig. 2). Ligated samples were 
transformed into DH5α by heat-shock (42 °C 
for 50 sec) method and positive clones with 
appropriate insert were screened out by use of 
LB agar plates containing 100 µg/ml 
ampicillin. Positive colonies containing the 
ligated constructs were transformed into 
BL21-RIL for the expression of type F 
recombinant domains. 
 
 
 
 
 
 
 
Expression and purification of 
recombinant proteins 
 
To monitor the induction of recombinant 
domains in BL21-RIL, 2 ml of transformant 
cultures were inoculated and grown in LB 
broth and induced at various time intervals 
using different concentrations of isopropyl 
β-D-1-thiogalactopyranoside (IPTG). In 
order to purify recombinant proteins, mass 
production was performed by inoculating 2 
ml induced culture in 1 liter followed by 
centrifugation (12,000 xg) at 4 °C for 20 
min. Pellet was then resuspended in 10 ml of 
50 mM phosphate buffered saline (PBS) and 
cells were then lysed by sonication, with 10 
short bursts of 30 sec followed by intervals 
of placing samples on ice for 1 min cooling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 (a) 2 (b) 
Fig.2: Schematic diagram of constructed plasmids generated by MacVector 10.0.2 software (Symantec Corporation). 
Plasmids pGEX-4T-1-F-LC (a) and pGEX-4T-1-F-HN (b) encoding catalytic and translocation domains. 
 
Nepal	  Journal	  of	  Biotechnology.	  	  Jan.	  2012,	  Vol.	  2,	  No.	  1:	  1	  –	  15	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Biotechnology	  Society	  of	  Nepal	  (BSN),	  All	  rights	  reserved	  
 5 
After centrifugation at 12,000 xg for 30 min, 
the pellet was resuspended in 10 ml PBS 
overnight at 4 °C and supernatant was placed 
in a GST affinity chromatography column 
after column was initially washed multiple 
times with deionized water and PBS, followed 
by normalization with GST resin. The large 
scale of GST-fusion proteins was eluted by 
single step affinity chromatography 
(containing sepharose 4B beads). Fractions 
containing desired proteins were pooled and 
dialyzed for 2 h at 4 °C against PBS. 
For thrombin protease treatment, resin bound 
GST-fusion proteins were cleaved with 20 
units thrombin incubating for 30 min at 37 °C 
followed by 15 min at room temp (20 - 25 °C) 
and final elution with 500 µl PBS. The eluted 
proteins were further dialyzed to maintain salt 
concentrations and pH. Protein concentrations 
were measured according to the Bradford 
method using a Bio-Rad model 550 microtiter 
plate reader. All proteins were labeled, 
aliquoted and stored at – 70 °C prior to use. 
Lastly, sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) was carried 
out on a 12% gel under reducing conditions in 
order to determine solubility of the eluted 
proteins. 
 
Production and analysis of polyclonal 
antibodies against rF-LC and rF-HN 
 
For immunization, three female Balb/c mice 
(four weeks old having around 18-22 gram 
body weight) were immunized 
intraperitoneally with 10 µg of antigen 
mixtures containing recombinant proteins (25 
µg GST free F-LC or 25 µg GST free F-HN) 
in PBS. Additionally, an equal volume of 
Freund’s complete adjuvant was separately 
injected into each mouse. After two weeks 
lapse, the mice were immunized with the 
mixture containing 20 µg of recombinant 
protein and equal volume of Freund’s 
incomplete adjuvant. At the start of the fourth 
week following the initial immunization, the 
mice were finally boosted by intravenous 
injection of the recombinant proteins (30 µg) 
without adjuvant. Three days following final 
boost, mice were then bled from the tail and 
tested by indirect ELISA.  
 
Preparation of monoclonal antibodies 
(hybridoma technology) 
 
Cell fusion and culture of hybridomas was 
carried out according to the protocol by 
Kohler et al. [24]. Briefly, cultures were 
incubated at 37 °C in an incubator with 5% 
CO2-in-air and 98% relative humidity. Four 
days following final boost, the mouse showing 
the highest antibody titer by ELISA was 
sacrificed by cervical dislocation and its 
spleen was removed aseptically. Spleen cells 
(1x108 viable cells) were mixed with SP2/0-
Ag 14 myeloma cells (1x107viable cells) and 
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grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) (Hyclone). The 
addition of 50% polyethylene glycol 4000 
(PEG) (Sigma Aldrich) allowed for the fusion 
of mixed cells; resulting in hybrid cells. 
Hybrid cells were screened by incubation in 
96-well plates (Nunc) containing 
hypoxanthine-aminopterin-thymidine (HAT) 
selection medium in combination with mouse 
feeder cells for one week. Antibody 
production from hybrid cells was monitored 
through indirect ELISA; positive cells were 
expanded into 24-well plates (Nunc) 
containing hypoxanthine-thymidine (HT) 
media supplemented with dilute aminopterin 
according to the standard protocol by Harlow 
and Lane [25]. ELISA-positive hybridomas 
were selected and cloned twice via limiting 
dilution; one cell per well into 96-well plates 
supplemented with HT media and feeder cells. 
Finally, cloned cell lines were grown in 
DMEM supplemented with 10% FBS and 
stored in liquid nitrogen. 
 
Indirect enzyme linked immunosorbent 
assay (ELISA)  
 
For the measurement of serum antibody titers, 
ELISA was performed as a standard protocol 
mentioned by Sigma Aldrich, with only minor 
modifications. Each well of 96 well plates 
(Nunc, Copenhagen, Denmark) was coated with 
antigen (100 µl containing 100 ng of either 
GST free recombinant protein or 100 ng 
BoNT/F) and incubated at 4 °C overnight. 
Each well was washed once with 200 µl of 
PBS containing 0.05% Tween 20 (PBST) and 
blocking solution (100 µl 1% skim milk) was 
added and incubated for 30 min at 37 °C. 
Following two more washes, the serum (1: 
1000 dilution) in PBS was added as the 
primary antibody. The plates were incubated 
at 37 °C for 90 min, and then washed three 
times as described above. Goat anti-mouse 
IgG conjugated with alkaline phosphatase was 
added as the secondary antibody (diluted 
1:2000 with PBS) and incubated for 2 h. After 
incubation with IgG, plates were washed four 
times prior to substrate treatment and 
visualization. Immobilized antigens were 
visualized with the p-Nitrophenyl phosphate 
(disodium) in substrate buffer containing 9.7% 
diethanolamine, and 1 mM MgCl2 and the 
resultant absorbance was measured at 415 nm 
with microplate reader (Model 550 Bio-Rad) 
for 5 - 10 min at 37 °C. 
 
Western blot analysis 
 
Western blot experimentation was adapted 
from previous methodology [26]. The protein 
samples were separated by SDS-PAGE and 
electroblotted for ~70 min by using 230 mA 
current onto a nitrocellulose membrane 
(Schleicher and Schuell Inc., NH, USA). 
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Subsequently, the membrane was blocked for 
nonspecific binding incubating with blocking 
solution for 1 h and then incubated with 
primary antibody overnight at room temp. The 
membrane was washed two times with PBST 
and incubated with alkaline phosphate 
conjugated goat anti-mouse IgG as a 
secondary antibody for 2 h. After washing 
three more times with PBST, the membrane 
was color developed by using 10 ml alkaline 
phosphate substrate solution, 50 µl nitro blue 
tetrazolium chloride, and 50 µl 5-bromo-4-
chloro-3-indolyl phosphate. 
 
Results and Discussion 
 
The cloning of both light and heavy chain 
domains using synthetic genes has been 
reported for various BoNTs [27-33]. However, 
there exist few studies on the cloning and 
expression of BoNT/F domains [34, 35]. 
Construction of recombinant plasmids 
containing pGEX-4T-1-F-LC, -HN, -HC, -
HCc was made for subsequent GST-tagged 
expression in E. coli. Initially, sequences of 
BoNT/F DNA domains were PCR amplified 
from genomic DNA of C. botulinum F str. 
Langeland and flanked by restriction sites 
(Table 1). Specifically, the amplified products 
were cloned into pGEX-4T-1 after digestion 
with respective restriction enzymes. Ligated 
constructs (for reference see schematic 
diagrams of constructed plasmids made by 
MacVector software 10.0.2, Fig. 2) were 
transformed into DH5α for propagation and 
positive colonies were identified after 
screening on plates containing ampicillin. 
Subsequently the recombinant plasmids were 
digested with restriction enzymes (Table 1) 
and appropriate band sizes were identified for 
both pGEX-4T-1 (4.9 kb) and all individual 
fragment sizes (Fig. 3). For confirmation of 
domain homology incorporated into our 
vector, sequencing was performed. After 
sequence analysis, plasmid DNA of positive 
clones had 100% identity with native 
sequences (data not shown).  
For protein expression, the four recombinant 
clones were transformed into E. coli BL21-
CodonPlus-RIL (strain used for protein 
expression with vectors driven by non-T7 
promoters). The BL21-CodonPlus-RIL was 
chosen because of its capability to express rare 
codons which allows for the high-level 
expression of recombinants [36]. Thus, BL21-
CodonPlus-RIL was a compatible host strain 
for our pGEX-4T-1 plasmid systems 
(containing a tac promoter). All domains were 
expressed in the form of fusion proteins with 
GST localized at the N-terminal of the fusion 
protein, enabling the  
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 (i) Visible bands of amplified F-LC product (3a), F-HN (3b), F-HC (3c), and F-HCc (3d); (ii) Endonuclease restricted bands of purified pGEX-
4T-1-F-LC with SalI/NotI (3a), pGEX-4T-1-F-HN (3b), pGEX-4T-1-F-HC (3c), and pGEX-4T-1-F-HCc (3d) with BamI/XhoI. 
M denotes DNA marker and Lane 1, DNA sample loaded. 
 
ease of purification using GST affinity 
chromatography. Expression of clostridial 
proteins at 37 °C has been shown to increase 
protein degradation [37], thus we chose an 
optimal temperature range of 20 - 25 °C for our 
expression studies. Conditions for expression 
of recombinant proteins were as follows: 7 h at 
24 °C using 0.5 mM IPTG concentration for 
GST-F-LC, 8 h at 22 °C using 0.4 mM IPTG 
concentration for GST-F-HN, 8 h at 20 °C 
using 0.25 mM IPTG concentration for GST-F-
HC, and 8 h at 20 °C using 0.10 mM IPTG 
concentration for GST-F-HCc. GST-F-LC and 
GST-F-HN induction was monitored by SDS-
PAGE (Fig. 4) and were found to be highly 
over-expressed in soluble form and purified at 
high concentrations.  
Despite induction at low temperature and IPTG 
concentrations, GST-F-HC and GST-F-HCc 
were expressed in inclusion bodies. Change in 
expression vectors from pGEX-4T-1 to pET-
32a(+) was then carried out in attempt to obtain 
soluble forms of GST-F-HC and GST-F-HCc. 
pET-32a(+) was subsequently transformed into 
BL21-CodonPlus(DE3)-RIL host cells, that 
utilizes the T7 RNA polymerase promoter. 
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Fig.3: Agarose gel (1%) electrophoresis of PCR product and restriction digested plasmid stained with ethidium bromide and visualized by UV  
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IPTG induction was carried out in a time dependent manner and SDS–PAGE (12 %) analysis of total lysate of E. coli BL21- (pGEX-4T-1-F-LC 
(a) and pGEX-4T-1-F-HN (b) with or without IPTG induction stained with Coomassie blue.  
Lane M: protein marker (Bio-Rad); Lanes 1 - 4: (0, 2, 5, and 7 h for F-LC and 0, 2, 5, and 8 h for F-HN) after IPTG induction. Lanes 2 - 4 
demonstrate expressed GST-F-LC a) and GST-F-HN (b) with treatment of IPTG. 
kDa, protein size expressed in kiloDalton. 
 
Although both vectors contain thrombin 
cleavage sites and are ideal for production of 
soluble proteins, neither one was able to alter 
the formation of inclusion bodies. Protein-
refolding procedures were performed using 
reducing reagents including various molar 
concentrations of urea or guanidine – HCl to 
solubilize the inclusion bodies but attempts 
were unsuccessful. As a result, only LC and 
HN domains were used for protein analysis 
and collection of polyclonal serum from 
immunized mice. GST affinity 
chromatography was then carried out to 
collect GST tagged LC and HN. After GST 
affinity chromatography and cleavage with 
thrombin protease treatment, recombinant 
GST free F-LC and GST free F-HN were 
analyzed on SDS-PAGE to monitor expected 
protein bands. SDS-PAGE revealed the 
appropriate size of both recombinants; GST 
fused 75 kDa and GST free 50 kDa (Fig. 5). 
Final recombinant protein concentrations were 
determined to be 1.0 mg/l. In order to analyze 
specificity of mice polyclonal sera against F-
LC and F-HN, mice were immunized 
intraperitoneally with antigens; GST free F-
LC and F-HN. To analyze the specificity of 
the polyclonal serums against F-LC and F-
HN, mouse polyclonal serum was collected 
from the tail vain and tested by Western 
blotting and indirect ELISA (both of these 
techniques being highly valuable in the 
detection of candidate biomarkers). The 
mouse anti-F-LC polyclonal antibodies were 
found to specifically recognize F-LC and 
BoNT/F (Figs. 5a and 6a). Similarly, anti-F-
HN polyclonal antibodies demonstrated a 
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Fig.4: Induction and expression analysis of recombinant proteins 
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strong affinity towards F-HN and native type 
F toxin (Figs. 5b and 6b). However, neither 
anti-F-LC nor anti-F-HN polyclonal 
antibodies were able to detect the HC domain 
(Fig. 5), validating the specificity of the 
polyclonal serums towards their respective 
region of BoNT/F. The designated 
recombinant domains have native structure as 
holotoxin and it was not unexpected for them 
to produce anti-sera against native toxin 
(BoNT/F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mouse showing highest immunoreactivity 
was then sacrificed in attempt to isolate a 
monoclonal antibody specific to F-LC or F-
HN domains. This could allow further 
research into the development of a highly 
effective neutralizing monoclonal antibody 
for a subunit vaccine and/or passive 
immunotherapy against BoNT/F. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (i) SDS–PAGE of purified GST F-LC and GST free F-LC (a) Purified GST F-HN and GST free F-HN (b) by single step GST affinity 
chromatography separated on a 12% gel and visualized by Coomassie blue stain; (ii) Western blot analysis performed by raising anti-F-LC (a) 
and anti-F-HN (b) mouse polyclonal antibody. 
Lane M: protein marker (Bio-Rad); Lane 1, GST-F-LC or HN; Lane 2, GST free-F-LC or HN; and Lane 3, unpurified GST-F-HC. 
Fig.5: Purification and characterization of recombinant BoNT/F domain proteins 
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Bar graph values represent interaction of anti F-LC (a) and anti-F-HN (b) mouse polyclonal serum antibody with: PC = BoNT/F as a coating 
antigen; S. 1 - 3 = samples of GST free F-LC (a) and GST free F-HN (b) coating antigens respectively & interaction of non-immunized mouse 
serum with: NC= GST free F-LC (a) and GST free F-HN (b) used as coating antigens respectively. 
Mouse polyclonal serum was harvested from three different mice (from different batches) immunized with GST free F-LC or GST free F-HN. 
PC- positive control, NC- negative control. n = 3 wells, two-tailed students t-test, S. 1 - 3 compared to NC, p < 0.05. 
 
Attempts were unsuccessful in isolating a 
monoclonal antibody specific towards our 
constructed BoNT/F domains (data not 
shown). However, we have successfully 
isolated a mouse monoclonal antibody that 
demonstrates neutralizing activity against 
native BoNT/F toxin resulting from BoNT/F 
toxiod in vivo immunization and hybridoma 
technology [38]. 
 
Conclusion 
 
This paper describes molecular and 
immunological studies on C. botulinum 
neurotoxin type F domains. Synthetic genes 
encoding BoNT/F partial fragments: catalytic 
domain (rF-LC), translocation domain (rF-
HN), receptor binding domain (rF-HC) and 
quarter part of HC (rF-HCc) were designed 
and cloned into E. coli. Additionally, 
expression, purification, and 
immunoreactivites were analyzed by Western 
blotting and indirect ELISA for LC and HN 
domains. The use of GST tagged recombinant 
protein technology was chosen in order to 
optimize detection and acquisition of high 
purity, stable, and soluble proteins through use 
of single step affinity chromatography. 
Although host strains, vector types, and 
induction conditions for expression were 
optimized to recover recombinant proteins in 
the soluble fraction, we were unable to purify 
HC and HCc. Immunoreactivity was accessed 
through GST free F-LC and F-HN through in 
vivo immunization and polyclonal serum 
antibody collection, proceeded by Western 
blotting and indirect ELISA.  
The anti-F-LC and anti-F-HN mouse 
6 (a)  6 (b)  
Fig.6:Immunoreactivity analysis by Indirect ELISA 
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polyclonal antibodies exhibited a strong 
affinity towards GST free and GST tagged F-
LC and F-HN respectively, while both 
recognized the native type F toxin. From this 
work, we conclude that purified BoNT/F LC 
and HN domains are capable of producing 
highly effective immunogens. Moreover, if 
future attempts prove fruitful in the isolation 
of monoclonal antibodies (that possess 
neutralizing activity), towards BoNT/F 
fragments, this may lead to more efficient 
protection against a high neurotoxin dose. 
Implications of this research could span across 
the development of therapeutic approaches, 
diagnostic detection systems, and vaccine 
candidacy for the protection and treatment of 
botulism as has been elucidated in previous 
work [34, 37, 39-42]. In summary, we have 
expressed both recombinant LC and HN 
domains of BoNT/F. The recombinant 
proteins are soluble; elicit an active immune 
response (polyclonal antibodies) in mice, 
making them ideal for investigators to process 
potential subunit vaccines towards BoNT/F. 
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